Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma

被引：17
|
作者：
Gautschi, Oliver [1 ]
Menon, Roopika [2 ]
Bertrand, Miriam [2 ]
Murer, Christian [1 ]
Diebold, Joachim [1 ]
机构：
[1] Cantonal Hosp Lucerne, Luzern, Switzerland
[2] NEO New Oncol GmbH, Cologne, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 01期
关键词：
D O I：
10.1016/j.jtho.2019.07.027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E13 / E15
页数：4
相关论文
共 50 条
  • [31] Low-dose osimertinib in an elderly with EGFR-mutant metastatic lung adenocarcinoma: A case report and literature review
    Dave Yahot, Kemuel
    Dy-Agra, Guinevere
    Luisa Tiambeng, Ma.
    Lynn Co, Jamie
    RESPIROLOGY, 2024, 29 : 83 - 83
  • [32] Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives
    Ricciuti, Biagio
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S249 - S252
  • [33] Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization
    Bolan, Patrick O.
    Zviran, Asaf
    Brenan, Lisa
    Schiffman, Joshua S.
    Dusaj, Neville
    Goodale, Amy
    Piccioni, Federica
    Johannessen, Cory M.
    Landau, Dan A.
    CELL SYSTEMS, 2020, 10 (01) : 52 - +
  • [34] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers Reply
    Schoenfeld, Adam J.
    Yu, Helena A.
    JAMA ONCOLOGY, 2020, 6 (12) : 1983 - 1983
  • [35] ERLOTINIB VERSUS RADIATION THERAPY FOR BRAIN METASTASES IN PATIENTS WITH EGFR-MUTANT LUNG ADENOCARCINOMA
    Gerber, Naamit K.
    Yamada, Yoshiya
    Shi, Weiji
    Zhang, Zhigang
    Riely, Gregory
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Rimner, Andreas
    Wu, Abraham J.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S902 - S902
  • [36] Deep learning radiopathomics predicts targeted therapy sensitivity in EGFR-mutant lung adenocarcinoma
    Taotao Yang
    Xianqi Wang
    Yuan Jin
    Xiaohong Yao
    Zhiyuan Sun
    Pinzhen Chen
    Suyi Zhou
    Wentao Zhu
    Wei Chen
    Journal of Translational Medicine, 23 (1)
  • [37] Effect of P. gingivalis on osimertinib resistance in EGFR-mutant lung cancer
    Li, Wendong
    Rotter-Maskowitz, Aviva
    Zhang, Keqiang
    Massarelli, Erminia
    Potempa, Jan
    Straussman, Ravid
    Raz, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma
    Gerber, Naamit K.
    Yamada, Yoshiya
    Rimner, Andreas
    Shi, Weiji
    Riely, Gregory J.
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Zhang, Zhigang
    Wu, Abraham J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (02): : 322 - 329
  • [39] Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
    Piper-Vallillo, Andrew J.
    Sequist, Lecia V.
    JACC: CARDIOONCOLOGY, 2019, 1 (02): : 179 - 181
  • [40] Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer.
    Blakely, Collin M.
    Gubens, Matthew A.
    Allen, Gregory M.
    Shah, Shrusti
    Jereza, Matthew
    Bacaltos, Bianca
    Bandyopadhyay, Sourav
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345